Subject(s)
Antibodies, Monoclonal, Humanized , Azetidines , Purines , Pyrazoles , Sulfonamides , Female , Humans , Middle Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Azetidines/therapeutic use , Drug Eruptions/etiology , Drug Eruptions/drug therapy , Facial Dermatoses/drug therapy , Neck/pathology , Purines/therapeutic use , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Treatment OutcomeSubject(s)
Antibodies, Monoclonal, Humanized , Azetidines , Purines , Pyrazoles , Sulfonamides , Humans , Sulfonamides/therapeutic use , Sulfonamides/adverse effects , Pyrazoles/adverse effects , Pyrazoles/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Azetidines/therapeutic use , Azetidines/adverse effects , Purines/therapeutic use , Purines/adverse effects , Neck/pathology , Female , Facial Dermatoses/drug therapy , Facial Dermatoses/chemically induced , Male , Treatment Outcome , Drug Eruptions/etiology , Drug Eruptions/drug therapy , Middle AgedSubject(s)
Erythema , Humans , Erythema/chemically induced , Erythema/drug therapy , Female , Facial Dermatoses/drug therapy , FaceABSTRACT
BACKGROUND: Idiopathic aseptic facial granuloma (IAFG) is an underrecognized pediatric skin disease, currently considered within the spectrum of rosacea. It usually manifests as a solitary, reddish, asymptomatic nodule on the cheek that resolves spontaneously. METHODS: Retrospective and descriptive observational study of 43 pediatric patients with a clinical diagnosis of IAFG, followed between 2004 and 2022, at two general hospitals in Argentina. RESULTS: IAFG predominated in girls (65%) and the average age of onset was about 6 years. A single asymptomatic nodule was seen in 79% of patients. The most common localization was the cheek (58%) followed by lower eyelids (41%). Family history of rosacea was present in 16% of patients. A concomitant diagnosis of rosacea and periorificial dermatitis was made in 14% and 9% of our population, respectively. Past or present history of chalazia was detected in 42% of the children. IAFG diagnosis was mainly clinical (88% of cases). Oral antibiotics were the most common indicated treatment (84%). Complete healing was achieved by the majority, but 18% of those with eyelid compromise healed with scars. CONCLUSIONS: IAFG is a benign pediatric condition that physicians should recognize in order to manage correctly. We herein refer to a particular morphologic aspect of IAFG lesions affecting the lower eyelids, where nodules adopt a linear distribution and have a higher probability of involute leaving a scar. Also, we consider that the concomitant findings of rosacea, periorificial dermatitis and chalazia in our patients, reinforce the consideration of IAFG within the spectrum of rosacea.
Subject(s)
Chalazion , Connective Tissue Diseases , Dermatitis , Facial Dermatoses , Rosacea , Female , Humans , Child , Retrospective Studies , Chalazion/complications , Chalazion/diagnosis , Facial Dermatoses/diagnosis , Facial Dermatoses/drug therapy , Facial Dermatoses/pathology , Granuloma/diagnosis , Granuloma/drug therapy , Rosacea/diagnosis , Rosacea/drug therapy , Rosacea/epidemiologyABSTRACT
BACKGROUND: Facial hyperpigmentation can negatively affect an individual's emotional and psychosocial well-being. AIMS: Assess safety and tolerability of a combination of microdermabrasion (DG) procedures using a novel brightening pro-infusion serum (EC-DG) with a targeted at-home treatment regimen in subjects with mild to severe facial hyperpigmentation, including melasma, post-inflammatory hyperpigmentation, and dark spots. PATIENTS/METHODS: This 12-week, open-label study enrolled 18 subjects (Fitzpatrick skin types I-IV) who underwent 6 in-office DG procedures with EC-DG (one procedure administered biweekly), along with daily topical application of a brightening treatment serum and dark spot cream. End points included change from baseline across multiple skin quality attributes and the Melasma Area and Severity Index (MASI), self-assessment questionnaires, and tolerability assessments. RESULTS: The combination treatment was well tolerated and resulted in significant (p ≤ 0.05) improvements from baseline in radiance, tactile roughness, and moisturization/hydration immediately after the first treatment, in MASI score at day 3, and in overall hyperpigmentation at week 4. Most (94.1%) subjects were satisfied with treatment. CONCLUSIONS: DG procedures using EC-DG combined with a targeted at-home skincare regimen are effective and tolerable for treating facial hyperpigmentation across a broad range of skin types.
Subject(s)
Dermabrasion , Hyperpigmentation , Severity of Illness Index , Humans , Female , Adult , Middle Aged , Hyperpigmentation/etiology , Hyperpigmentation/drug therapy , Dermabrasion/adverse effects , Dermabrasion/methods , Dermabrasion/instrumentation , Male , Treatment Outcome , Melanosis/therapy , Melanosis/drug therapy , Melanosis/diagnosis , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Administration, Cutaneous , Skin Lightening Preparations/administration & dosage , Skin Lightening Preparations/adverse effects , Young Adult , Facial Dermatoses/drug therapy , Facial Dermatoses/therapy , FaceSubject(s)
Facial Dermatoses , Hyperpigmentation , Lupus Vulgaris , Rosacea , Humans , Minocycline/adverse effects , Rosacea/chemically induced , Rosacea/diagnosis , Rosacea/drug therapy , Hyperpigmentation/chemically induced , Hyperpigmentation/diagnosis , Facial Dermatoses/chemically induced , Facial Dermatoses/diagnosis , Facial Dermatoses/drug therapyABSTRACT
BACKGROUND: Therapeutic make-up has previously been proven to be efficacious in improving the quality of life of patients with facial dermatoses, but its efficacy has only been assessed in the short term (less than one month). OBJECTIVES: This study aimed to determine whether the effect of therapeutic make-up on patients' quality of life persists in the longer term, i.e., after one year. MATERIALS & METHODS: This study included 53 patients who benefited from a therapeutic make-up consultation in the context of various facial dermatoses (pigmentation disorders, scars, acne, rosacea, eczema, adverse events of chemotherapy, etc.). Patients were asked to complete a quality-of-life questionnaire to obtain the Skindex score at baseline, and one month (M1) and one year (M12) after the first consultation. The difference in scores between baseline and M12 was calculated and Student's t-test was used to assess the significance of the values. RESULTS: Our results showed a significant difference (p<0.001) with an improvement in quality-of-life score by more than 10% between baseline and M12, for all the dimensions of the score (Emotion, Symptoms and Functioning). Based on the subgroup analysis, this score particularly improved for patients suffering with acne or rosacea (p=0.009) and scars (p=0.43), as well as for younger patients (<30 years old) (p=0.009). CONCLUSION: This is the first study to demonstrate a persistent long-term effect of therapeutic make-up on the quality of life of patients with facial dermatoses.
Subject(s)
Acne Vulgaris , Facial Dermatoses , Rosacea , Humans , Adult , Cicatrix/pathology , Quality of Life , Acne Vulgaris/drug therapy , Rosacea/drug therapy , Facial Dermatoses/drug therapyABSTRACT
Aseptic facial granuloma is a rare pediatric disease, presenting with asymptomatic facial nodules on the cheeks or the eyelids and may represent a form of granulomatous rosacea in children. In this retrospective case series, 12 children with aseptic facial granuloma were treated with oral macrolides (erythromycin or roxithromycin) resulting in a healing of the lesions within a mean treatment time of 5.25 months with no recurrences. The treatment was mainly well tolerated. Oral macrolides may be effective in the treatment of patients with aseptic facial granuloma.
Subject(s)
Facial Dermatoses , Rosacea , Child , Humans , Macrolides/therapeutic use , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Granuloma/drug therapy , Granuloma/pathology , Rosacea/drug therapy , Cheek/pathology , Facial Dermatoses/drug therapy , Facial Dermatoses/pathologyABSTRACT
For legal reasons, the publisher has withdrawn this article from public view. For additional information, please contact the publisher.
Subject(s)
Cellulitis , Facial Dermatoses , Herpes Simplex , Wrestling , Humans , Male , Asian People , Cellulitis/drug therapy , Cellulitis/etiology , Cellulitis/virology , Republic of Korea , Sports , Herpesvirus 1, Human , Herpes Simplex/drug therapy , Herpes Simplex/etiology , Herpes Simplex/virology , Facial Dermatoses/drug therapy , Facial Dermatoses/etiology , Facial Dermatoses/virology , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , AdolescentSubject(s)
Facial Dermatoses , Rosacea , Humans , Child , Facial Dermatoses/diagnosis , Facial Dermatoses/drug therapyABSTRACT
Não se aplica, trata-se de uma carta
Not applicable, this is a letter.